In this episode (21:54 min), Medicom’s correspondent covers 6 presentations from the ASCO’s Genitourinary Cancers Symposium (ASCO GU 2022, or #GU22), which was held as a hybrid event from 17-19 February 2022, in San Francisco, California.
1. Continued enzalutamide + docetaxel offers clinical benefit for patients who progress on enzalutamide
In patients with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with docetaxel plus prednisolone who have progressed on enzalutamide, continuation of enzalutamide plus docetaxel led to a significant improvement of progression-free survival, results from the PRESIDE study show.
2. Darolutamide improves OS in patients with mHSPC
The androgen receptor inhibitor darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel improved overall survival in patients with metastatic hormone-sensitive prostate cancer (mHSPC), results from the ARASENS trial show.
3. High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib
Results of the NeoAvAx trial indicate that the neoadjuvant combination of immune checkpoint inhibitor avelumab plus VEGF inhibitor axitinib has potential for use in patients with high-risk, non-metastatic, clear-cell renal cell carcinoma (RCC).
4. Disease-free survival benefits with adjuvant pembrolizumab in RCC persist with longer follow-up
Updated data from the KEYNOTE-564 trial shows continuous disease-free survival advantage with pembrolizumab versus placebo as neoadjuvant therapy for renal cell carcinoma (RCC). With 33% of events needed, overall survival data are not yet mature; however, the hazard ratio is declining.
5. Atezolizumab does not improve survival in advanced penile cancer trial
The phase 2 PERICLES trial examining atezolizumab with or without radiotherapy in patients with advanced squamous cell carcinoma of the penis missed its primary endpoint of 1-year progression-free survival ≥35%.
6. Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma
Results from the ATLANTIS trial platform indicate that rucaparib could play a role in the maintenance treatment of metastatic urothelial carcinoma with a DNA repair deficiency that has responded to first-line platinum-based chemotherapy.
Enjoy listening!
Copyright ©2022 Medicom Medical Publishers
Posted on
Table of Contents: ASCO GU 2022
Featured articles
Prostate Cancer
First-line treatment with olaparib significantly improves PFS in mCRPC
First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC
Darolutamide improves OS in mHSPC
Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide
Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence
PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel
Artificial intelligence improves prediction of long-term outcomes
Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer
Addition of abiraterone to ADT/docetaxel does not increase bone loss
Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity
Urothelial Carcinoma
No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma
Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma
Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC
Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma
Maintenance niraparib fails to improve PFS in advanced urothelial cancer
First-line avelumab shows clinical activity in advanced urothelial carcinoma
Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma
Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma
Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer
Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin
Renal Cell Carcinoma
High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib
DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up
Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC
Combined nivolumab/axitinib treatment elicits good response in metastatic RCC
Folliculin mutations not associated with sporadic chromophobe RCC
Differential patterns of molecular alterations among sites of metastasis in RCC
Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC
Penile & Testicular Cancer
HPV-positive and HPV-negative penile squamous cell carcinoma are molecularly distinct tumours
Atezolizumab does not improve survival in advanced penile cancer
Biomarkers to distinguish necrosis from teratoma before pcRPLND in testicular cancer
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com